Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 10/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 10/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.53 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.53 |
| ▸ | KCNE1 | P15382 | 7/20 | 0.53 |
| ▸ | KCNQ1 | P51787 | 7/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160402 | 0.88 | KCNQ3 (0.60) | RAB9ASMN1; SMN2KCNQ3KCNQ2KCNE1 | |
| SCHEMBL14885954 | 0.86 | P2RX1 (0.70) | KCNQ3KCNQ2F10P2RX1TMPRSS4 | |
| SCHEMBL14363272 | 0.86 | PLAU (0.58) | RAB9ASMN1; SMN2PLAUF2F10 | |
| SCHEMBL14363269 | 0.82 | KMT2A (0.59) | RAB9ASMN1; SMN2PLAUF2F10 | |
| SCHEMBL24460276 | 0.81 | P2RX1 (0.77) | RAB9ASMN1; SMN2PLAUF2F10 | |
| SCHEMBL21021862 | 0.81 | PLAU (0.73) | RAB9ASMN1; SMN2PLAUF2F10 | |
| SCHEMBL14363284 | 0.79 | HDAC3 (0.62) | RAB9ASMN1; SMN2PLAUF2F10 | |
| SCHEMBL13947174 | 0.79 | RAB9A (0.83) | RAB9ASMN1; SMN2KCNQ3KCNQ2KCNE1 | |
| SCHEMBL330475 | 0.79 | P2RX1 (0.74) | RAB9APLAUF2F10PLAT | |
| SCHEMBL14363184 | 0.78 | PLAU (0.69) | RAB9ASMN1; SMN2PLAUF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | RAB9A 3765/4885SMN1; SMN2 2862/4885KCNQ3 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.